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The present study reported that the ubiquitin ligase Cbl-b was up-regulated during anthracycline-
induced apoptosis in two cell lines, RBL-2H3 leukemia cells and MGC803 gastric cancer cells. Over-
expression of Cbl-b strongly promoted the cytotoxic and apoptosis-inducing effects of anthracy-
clines, while a dominant negative (DN) Cbl-b mutation abolished these effects in both cell lines.
Further investigation revealed that mitochondrial depolarization was enhanced by Cbl-b and
decreased by Cbl-b (DN) in RBL-2H3 cells. Moreover, overexpression of Cbl-b signiﬁcantly suppressed
ERK activation, and Cbl-b (DN) strongly enhanced both ERK and Akt activation. Altogether, these
results indicate that Cbl-b sensitized both leukemia and gastric cancer cells to anthracyclines by
activating the mitochondrial apoptotic pathway andmodulating the ERK and Akt survival pathways.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Anthracyclines are a group of antibiotics that are among the
most potent chemotherapeutic agents known. They drive cancer
cells into apoptosis mainly through the ability to disturb DNA func-
tion and to induce DNA damage [1]. They are highly effective
against a broad spectrum of malignancies. Epirubicin (EPI) is used
against lymphoma, gastric cancer, small cell lung cancer and breast
cancer. And Daunorubicin (DNR) is used to combat leukemia with
the dose-dependent accumulating toxicity [2–6]. A series of stud-
ies have recently indicated that the administration of chemothera-
peutic agents commonly resulted in modulation of the
phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal
regulated kinase (ERK) pathways, which are known to regulate
fundamental cellular functions such as cell growth and survival
[7,8]. For example, the combination of the PI3K inhibitors wort-
mannin and LY294002 enhanced the cytotoxicity of adriamycin
[9–11]. On the other hand, drug-resistant cells had higher levelschemical Societies. Published by E
.of activated Raf/mitogen-activated protein/extracellular signal-
regulated kinase (MEK)/ERK signaling and decreased induction of
apoptosis when exposed to doxorubicin [12]. These reports suggest
that the PI3K/Akt and MEK/ERK pathways antagonized anthracy-
cline-induced apoptosis, and that molecules suppressing these
pathways might promote anthracycline chemosensitivity.
Cbl-b is an E3 ubiquitin ligase which plays an important role in
T and B cell immune function [13,14], mast cell activation, cell
adhesion and migration, and leukemia leukemiogenesis [15–18].
It was reported that Cbl-b overexpression strongly inhibits ERK
activation in mast cells [16]. Cbl-b/ T cells have increased Akt
and ERK phosphorylation and sequential deregulation of late T cell
proliferation [13]. Although there is not yet direct evidence, these
data imply that Cbl-b might also participate in regulating tumor
cell sensitivity to anthracyclines through the modulation of the
PI3K/Akt and MEK/ERK survival pathways.
The aim of the present study was to explore the effects of the
ubiquitin ligase Cbl-b on the chemosensitivity of anthracyclines.
The results showed that Cbl-b sensitized both the leukemia cell
line RBL-2H3 and the gastric cancer cell line MGC803 to anthracy-
clines, and that this sensitization depended on its ubiquitin ligase
activity. Further exploration validated that overexpression oflsevier B.V. All rights reserved.
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strongly enhanced both ERK and Akt activation. These data gave
us new insight into the regulatory mechanism of anthracycline
chemosensitivity.
2. Materials and methods
2.1. Materials and antibodies
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT), dimethyl sulfoxide (DMSO) and the speciﬁc PI3K inhibitor
LY294002, MEK/ERK inhibitor PD98059 were from Sigma (St. Louis,
MO). Antibody against Cbl-b was from Santa Cruz Biotechnology
(Santa Cruz, CA). Antibodies speciﬁc to Akt and phospho-Akt (pAkt)
were from Cell Signaling Technology (Danvers, MA). Anti-ERK,
anti-pERK, and anti-tubulin antibody was from BD Biosciences
Pharmingen (San Jose, CA).
2.2. Cell culture
The rat basophilic leukemia (RBL-2H3) cell line was grown in
DMEM (Sigma, St. Louis, MO) medium containing 10% heat-inacti-
vated fetal calf serum (FCS) in a 37 C humidiﬁed incubator with a
mixture of 95% air and 5% CO2.
Human gastric cancer MGC803 cells were grown in RPMI1640
(Gibco, Gaithersburg, MD) medium containing 10% heat-inacti-
vated FCS in a 37 C humidiﬁed incubator with a mixture of 95%
air and 5% CO2.
2.3. Patients and tissue samples
The ﬁles of 13 surgically resected gastric cancer cases examined
at the Department of Pathology, the First Hospital of China Medical
University, between 1 August 2007 and 31 December 2008 were
analyzed. No patient had received preoperative chemo- or radio-
therapy. This study was approved by the Human Ethics Review
Committee of China Medical University, informed consent was ob-
tained from all patients in accordance with the Declaration of Hel-
sinki and its later revision.
2.4. MTT assay
The effects of different agents on cell proliferation were mea-
sured using MTT assay as described previously [19]. Brieﬂy, cells
were seeded at 1  104/well in 96-well plates and incubated
overnight; different concentrations of the test agent were then
added and incubation continued for 24 h. Thereafter, 20 ll of
MTT solution (5 mg/ml) was added to each well and the cells
incubated for a further 4 h at 37 C. After removal of the culture
medium, cells were lysed in 150 ll of DMSO and the optical den-
sity (OD) measured at 570 nm using a microplate reader (Bio-
Rad, Hercules, CA). The following formula was used: cell viabil-
ity = (OD of the experimental sample/OD of the control
group) 100%.2.5. Western blot analysis
Total cellular proteins were extracted and quantiﬁed as de-
scribed previously. Aliquots (50 lg) of each lysate were electro-
phoresed on SDS–PAGE gels and then blotted onto nitrocellulose
membranes. Membranes were blocked with 5% non-fat milk in
TBST (10 mM Tris–HCl pH 7.4, 100 mM NaCl, 0.5% Tween-20) for
2 h at room temperature. Membranes were then incubated over-
night at 4 oC in 5% non-fat milk in TBST containing either pAkt,
Akt, Cbl-b, pERK, ERK or tubulin antibodies, followed by 1 h incu-bation with the peroxidase-conjugated second antibody. After
extensive washing (TBST) proteins were visualized using the en-
hanced chemiluminescence reagent (SuperSignal West Pico
Chemiluminescent Substrate; Pierce, Rockford, IL). The ﬁnal result
was analyzed by NIH Image J software.
2.6. Reverse-transcription-polymerase chain reaction (RT–PCR)
Total RNA was extracted from each biopsy by the TRIzol Plus
RNA Puriﬁcation Kit (Invitrogen, Carlsbad, CA) from 13 pairs of tu-
mor tissue and matched normal mucosa. RT–PCR was performed
with primer pairs for Cbl-b: forward (50-CCGGTTAAGTTGCACTC
GAT-30) and reverse (50-CAAAGGGGTCCAC GATTATG-30). PCR con-
ditions were 95 C for 5 min, 30 cycles of 95 C for 30 s, 59 C for
30 s, and 72 C for 30 s and one cycle at 72 C for 7 min. The results
were visualized under UV illumination.
2.7. Flow cytometry
Cells were cultured in the presence or absence of DNR or EPI for
the indicated times. Cells were then harvested and ﬁxed with ice-
cold 70% (v/v) ethanol for 24 h. After centrifugation at 200g for
5 min, the cell pellet was washed with PBS (pH 7.4) and was resus-
pended in PBS containing propidium iodide (10 lg/ml) and DNase-
free RNase (20 lg/ml). Cells were then incubated at room temper-
ature in the dark for 30 min, and DNA content was determined by
ﬂow cytometry using a FACScan ﬂow cytometer (Becton Dickinson,
San Jose, CA), and data were analyzed using MODIFIT software
(Becton Dickinson, San Jose, CA) [20].
Mitochondrial depolarization was determined by means of the
cationic lipophilic ﬂuorochrome DioC6 (3), which accumulated in
the mitochondrial matrix driven by the DWm. For quantitation of
cells with reduced DWm, 4  105 cells/well were incubated in
2 ml of culture medium in 6-well plates and incubated overnight,
and then DNR and EPI were added and further incubated for
24 h. Thereafter, cells were harvested, washed, and incubated for
15 min in culture medium containing 20 nm of DioC6(3) (Sigma–
Aldrich, St. Louis, MO). The percentage of DWm low cells was deter-
mined by ﬂow cytometry.
2.8. Transfections of plasmid constructs
Gastric cancer cells were plated at a density of 4  105 cells in
6-well dish 24 h before transfection. The cDNA encodes Cbl-b
was obtained from Dr. Stanley Lipkowitz (National Naval Medical
Center, Bethesda, MD) and subcloned into pcDNA expressing vec-
tor [16]. Dominant negative form of Cbl-b (Cbl-b (DN)), which is
a mutant form with a Cys373 to Ala (C373A) and has no ubiqui-
tin-protein ligase function was described previously [16]. Cbl-b/
pcDNA3.1 and Cbl-b (DN)/pcDNA3.1 were transiently transfected
using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA)
according to the protocol suggested by the manufacturer. Empty
vector was used as the transfection control.3. RNA interference
Two sets of synthetic oligonucleotides involved the sense and
antisense target sequences of human Cbl-b: 50-GAT
CCCGGACAGACGGAATCTCACATTGATAT CCGTGTGAGATTCCGTCT
GTCCTTTTTTCCAAA-30 and 50-AGCTTTTGGAAA AAAGGACAGACG
GAATCTCACACGGATATCAATGTGAGATTCCGTCTGTCCGG-30 for
Cbl-b (414), and 50-GATCCCGTTTCCGGTTAAGTTGCACTCGTTCA
AGAGACGAGTGCAACTTAACCGGAAATTTTTTCCAAA-30 and 50-
AGCTTTTGGAAAAAATTTCCGGTTAAGTTGCACTCGTCTCTTGAACGAG
TGCAACTTAACCGGAAAGG-30 for Cbl-b (852), and one set of
Fig. 1. Effects of DNR and EPI on RBL-2H3 cell and gastric cancer cell viability and apoptosis. (A and C) RBL-2H3 cells and MGC803 cells were treated by the indicated
concentrations of DNR or EPI for 24 h, and then cell viability was tested by MTT assay. Then the statistic analysis was done to compare untreated samples and different
concentration treated samples (*, #P < 0.05, #DNR group, *EPI group). The percentage of untreated samples is 100%. (B and D) RBL-2H3 and MGC803 cells were treated by
19.64 nM DNR or 139.01 nM EPI for 8 and 24 h, then apoptosis status was observed by ﬂow cytometry, and results were analyzed by Modiﬁt software. Data are means ± S.Ds.
*, #P < 0.05. Representative results from at least three individual experiments are shown.
Fig. 2. Effects of DNR and EPI on Cbl-b expression in RBL-2H3 cell and gastric cancer cell. (A and C) RBL-2H3 cells and MGC803 cells were treated by DNR or EPI, and then Cbl-
b expression was tested by Western blot. (B) Total RNAs were isolated from 13 pairs of gastric cancer tissues and matched normal mucosa, then Cbl-b mRNA expression was
detected by RT–PCR. The expression of GAPDH was used as internal control. C indicated gastric cancer tissues, N indicated matched normal mucosa, M indicated marker, W
indicated water.
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GACACGTTCGGAGAATTTTTTCCAAA-30 and 50-AGCTTTTGGAAAAAA
TTCTCCGAACGTGTCACGTCGGATATCZAACGTGACACGTTCGGAG
AACGG-30 for nonsilencing control were phosphorylated by T4 ki-
nase (Takara, Tokyo, Japan), annealed, and ligated into the Bam-HI/HindIII-cleaved backbone of pRNA-U6.1/Neo (Genscript,
Piscataway, NJ). SiRNA expressing vectors were transiently trans-
fected into MGC803 cells using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA). After siRNA had been transfected for
48 h, the protein of the cells was extracted and quantiﬁed.
Table 1
IC50 values obtained following treatment with DNR and EPI in Cbl-b and Cbl-b (DN)
overexpressing RBL-2H3 cells. Data are means ± S.Ds. *, #P < 0.05.
IC50 (nM) Vector Cbl-b Cbl-b (DN)
DNR 19.64 ± 2.3 12.74 ± 1.6# 105.71 ± 6.5#
EPI 139.01 ± 4.5 95.61 ± 2.9* 217.8 ± 8.7*
2258 X. Qu et al. / FEBS Letters 583 (2009) 2255–22624. Statistical analysis
Data are presented as means ± S.D. The signiﬁcance of the dif-
ference between the groups was assessed by the Student two-
tailed t-test. P value of less than 0.05 was considered signiﬁcant.
All means were calculated from at least three independent
experiments.
5. Results
5.1. Effects of DNR and EPI on cell viability, apoptosis, and Cbl-b
expression in RBL-2H3 leukemia cells and MGC803 gastric cancer cells
To investigate the effects of DNR and EPI on cell viability, RBL-
2H3 cells were incubated in the presence of DNR or EPI for 24 h.
As conﬁrmed by MTT assay, DNR and EPI triggered dose dependent
cytotoxicity (Fig. 1A). The IC50s were 19.64 nM for DNR and
139.01 nM for EPI. Then apoptosis was measured after exposure
to 19.64 nM DNR and 139.01 nM EPI for 8 and 24 h. As shown in
Fig. 1B, the percentage of apoptotic cells was about 20% in theFig. 3. Effects of Cbl-b on DNR and EPI chemosensitivity. (A) Cells were treated with
transfected by Vector, Cbl-b and Cbl-b (DN), followed with the treatment of 1 lM EPI for 8
b, followed with the treatment of 1 lM EPI for 24 h. Then apoptotic cells were observed
means ± S.Ds. *, #P < 0.05. Representative results from three individual experiments areDNR treated group and 15% in the EPI treated group at 8 h, and
55% in the DNR treated group and 45% in the EPI treated group
at 24 h. Similar result was also observed in gastric cancer cell line
MGC803 (Fig. 1C and D). Meanwhile, time-dependent Cbl-b up-
regulation was detected in RBL-2H3 cells (Fig. 2A). Cbl-b was also
expressed by 76.9% gastric cancer tissue cells, by 38.6% matched
normal tissue cells (Fig. 2B). The present results showed that EPI
also up-regulated the expression of Cbl-b (Fig. 2C). These results
indicate that apoptosis was induced by these anthracyclines in a
time-dependent manner. Cbl-b might be involved in the regulation
of anthracycline chemosensitivity.
5.2. Effects of Cbl-b on DNR and EPI chemosensitivity in RBL-3H3 cells
and MGC803 cells
In order to investigate the effects of Cbl-b on anthracycline
chemosensitivity, previously established RBL-2H3 cells transfected
with Cbl-b were used for further experiments [17]. Overexpression
of Cbl-b did not obviously affect the proliferation of RBL-2H3 cells
and MGC803 cells, while Cbl-b (DN) strongly accelerated both of
cells proliferation by around 1.5 times compared to the control
cells (data not shown). Cbl-b obviously decreased the IC50s of
DNR and EPI from 19.64 nM and 139.01 nM to 12.4 nM and
95.61 nM, respectively. In contrast, Cbl-b (DN) signiﬁcantly pro-
moted the IC50 values to 105.71 nM in the DNR treated group
and 217.8 nM in the EPI treated group (Table 1). Furthermore,
the ﬂow cytometric results revealed that wild type Cbl-b signiﬁ-
cantly enhanced DNR-induced apoptosis from 19.3% to 33.5% at
8 h, while Cbl-b (DN) reversed the promoting effect back to19.64 nM DNR and 139.01 nM EPI for 8 h. (B) Gastric cancer cells MGC803 were
h. (C) Gastric cancer cells MGC803 were transfected by Vector, ShRNA1, 2, 3 for Cbl-
by ﬂow cytometry, and ﬁnal results were analyzed with Modiﬁt software. Data are
shown.
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(Fig. 3A). On the other hand, EPI-induced MGC803 gastric cancer
cell apoptosis was increased from 9.52% to 34.2% by wild type
Cbl-b at 8 h, but decreased to 3.12% by Cbl-b DN (Fig. 3B). Further-
more, knockdown of Cbl-b decreased the apoptosis from 28.7% to
around 15% after exposed to EPI for 24 h (Fig. 3C) in MGC803 cells.
These results indicated that Cbl-b could promote anthracycline
chemosensitivity not only in leukemia cells but also in gastric can-
cer cells. And the promoting effects were dependent on its ubiqui-
tin ligase activity.5.3. Effects of Cbl-b on DNR and EPI-induced mitochondrial
depolarization
It is reported that anthracyclines trigger the intrinsic apopto-
tic pathway when they induce apoptosis. Therefore the effect of
Cbl-b on mitochondrial depolarization was examined. As shown
in Fig. 4, Cbl-b facilitated both DNR and EPI-induced reduction
of mitochondrial membrane potential, and a point mutation in
its RING ﬁnger domain reversed this decrease almost back to
control levels. These results suggest that Cbl-b promotes anthra-
cycline chemosensitivity partially through enhancing mitochon-
drial depolarization.Fig. 4. Effects of Cbl-b on DNR and EPI-induced mitochondria depolarization. Cells we
analysis of mitochondrial membrane potential was performed using staining with DioC6
experiments are shown. Both of the results were also summarized in the lower column5.4. Effects of Cbl-b on DNR and EPI-induced Akt and ERK activation
Since the PI3K/Akt and MEK/ERK signaling pathways promote
survival and thereby antagonize anthracycline-induced cancer cell
apoptosis [8,9,20,21], Akt and ERK activation was examined. As
shown in Figs. 5A and 6A, both Akt and ERK were transiently acti-
vated in DNR and EPI treated parental cells. The PI3K inhibitor
LY294002 promoted DNR and EPI-induced apoptosis from 10.32%
and 3.91% to 47.88% and 52.36%, respectively (Fig. 5B). Meanwhile,
theMEK inhibitor PD98059promotedDNRandEPI-induced apopto-
sis from 10.32% and 3.91% to 49.46% and 46.63%, respectively
(Fig. 6B). Western blot results revealed that Cbl-b signiﬁcantly sup-
pressed anthracycline-induced ERK activation, and Cbl-b (DN)
strongly increased Akt and ERK activation compared to controls
(Figs. 5C and 6C). Furthermore, LY294002 andPD98059 resensitized
cells with overexpression Cbl-b (DN) to anthracyclines (Figs. 5D and
6D). These results imply that Cbl-b might enhance DNR and EPI-in-
duced apoptosis by modulating the PI3K and ERK pathways.6. Discussion
Constant doxorubicin treatment induces serious cumulative
dose related cardiotoxicity. This is one of the major obstaclesre treated by 19.64 nM DNR or 139.01 nM EPI for 8 h. Thereafter, ﬂow cytometric
(3). Data are means ± S.Ds. *, #P < 0.05. Representative results from three individual
graph.
Fig. 5. Effects of Cbl-b on DNR and EPI-induced Akt activation. (A) RBL-2H3 parental cells were treated by 19.64 nM DNR and 139.01 nM EPI for 8 and 16 h, then pAkt and Akt
were detected. (B and D) RBL-2H3 parental cells (B) and cells overexpressing Cbl-b (DN) (D) were pretreated by 25 lM Ly294002 for 1 h, followed by treatment of 19.64 nM
DNR and 139.01 nM EPI for 5 h, then apoptosis was detected by ﬂow cytometry, and the data were analyzed by Modiﬁt software. Data are means ± S.Ds. *, #P < 0.05. (C) Cells
were treated by 19.64 nM DNR and 139.01 nM EPI for 8 h, the expression of pAkt and Akt was detected. Representative results from three individual experiments are shown.
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mination of therapy [1–3]. Therefore, the investigation of anthra-
cycline-induced signaling pathways in cancer cells is needed to
lower the administration dose and thereby delay the cumula-
tive-dose related toxicity of anthracycline treatment. The E3
ubiquitin ligase Cbl-b is a multi-functional molecule. Cbl-b
expression is required for apoptosis in activation-induced T help-
er cells [13–16]. Our previous results showed that Cbl-b is in-
volved in bufalin-induced gastric cancer cell apoptosis [19]. The
present study revealed that Cbl-b was up-regulated during DNR
and EPI-induced apoptosis in RBL-2H3 leukemia cells and
MGC803 gastric cancer cells. Cbl-b overexpression promoted
the viability-inhibiting and apoptosis-inducing effects of anthra-
cyclines in both cell types, while Cbl-b (DN) signiﬁcantly abol-
ished these effects. Meanwhile knockdown of Cbl-b expression
desensitized MGC803 cells to EPI. Further exploration revealed
that Cbl-b promoted anthracycline triggered mitochondrial depo-
larization in an ubiquitin ligase activity dependent manner.
These results indicate that Cbl-b might promote anthracycline
chemosensitivity in RBL-2H3 cells partially through activating
the intrinsic mitochondrial apoptotic pathway, and that this
mechanism is dependent on Cbl-b’s ubiquitin ligase activity.
It is reported that activation of the PI3K/Akt signaling pathway
attenuates anthracycline’s effects, and that speciﬁc inhibitors can
sensitize cancer cells to anthracyclines [22,23]. The present study
showed that DNR and EPI activated Akt, and that the PI3K inhibitor
LY294002 enhanced DNR and EPI-induced apoptosis in RBL-2H3
cells. These results conﬁrmed that in the treatment of RBL-2H3cells with anthracyclines, PI3K/Akt is the pathway that blocks
apoptosis. Meanwhile, Cbl-b negatively regulates the PI3K/Akt
pathway during T, B and mast cell activation by ubiquitinating
the P85 subunit of PI3K [14–16]. Cbl-b deﬁciency results in hyper-
active PI3K/Akt [14,15]. In the present study, although wild type
Cbl-b did not obviously suppress Akt activation, the loss of function
mutation of Cbl-b strongly increased Akt activation in anthracy-
cline-induced leukemia cell apoptosis. Furthermore, Ly294002
resensitized Cbl-b (DN) overexpressing cells to anthracyclines. This
indicates that Cbl-b (DN) desensitization of leukemia cells to anth-
racyclines might be through enhancement of the Akt signal
pathway.
The MEK/ERK signaling pathway activation is another pathway
which attenuates anthracyclines effects, and its speciﬁc inhibitors
also sensitize cancer cells to anthracyclines [24,25]. Cbl/Cbl-b also
negatively regulates the MEK/ERK pathway in T, B and mast cells
[26,27], probably through the Fyn–Cbl–Rap1 pathway, which
antagonizes Ras function by sequestering Raf-1 kinase and pre-
venting activation of the MAPK cascade and downstream transcrip-
tion factors [28–30]. The present study showed that DNR and EPI
also activated ERK, and that the MEK/ERK inhibitor PD98059 en-
hanced DNR and EPI-induced RBL-2H3 cells apoptosis. Further-
more, Cbl-b inhibited anthracycline induced ERK activation,
while Cbl-b (DN) partially reversed the inhibiting effects. Further-
more, PD98059 resensitized Cbl-b (DN) overexpressing cells to
anthracyclines. These data indicate that Cbl-b sensitization of leu-
kemia cells to anthracyclines might be through inhibition of the
ERK signaling pathway.
Fig. 6. Effects of Cbl-b on DNR and EPI-induced ERK activation. (A) RBL-2H3 parental cells were treated by 19.64 nM DNR and 139.01 nM EPI for 8 and 16 h, pERK and ERK
were detected. (B and D) RBL-2H3 parental cells (B) and cells overexpressing Cbl-b (DN) (D) were pretreated by 10 lM PD98059 for 1 h, followed by treatment of 19.64 nM
DNR and 139.01 nM EPI for 5 h, then apoptosis was detected by ﬂow cytometry, and the data were analyzed by Modiﬁt software. Data are means ± S.Ds. *, #P < 0.05. (C) Cells
were treated by 19.64 nM DNR and 139.01 nM EPI for 8 and 16 h, pERK and ERK were detected. Representative results from three individual experiments are shown.
X. Qu et al. / FEBS Letters 583 (2009) 2255–2262 2261In summary, Cbl-b promoted chemotherapeutic sensitivity of
anthracyclines at least partially through facilitating the intrinsic
mitochondria pathway and modulating the MEK/ERK and PI3K/
Akt survival pathways, and this inhibitory effect is dependent on
its ubiquitin ligase activity.
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